Cancer-focused biotech Anixa Biosciences announced plans to invest in Bitcoin to strengthen its financial strategy and enhance shareholder value.
The San Jose-based biotech firm stated in a Nov. 22 press release that it will allocate a portion of its treasury to Bitcoin (BTC), citing the asset’s “unique inflation-resistant qualities.”
In a Nov. 22 press release, Anixa said the move has been approved by its board as part of a broader strategy to diversify its cash holdings. The biotech firm emphasized its “strong balance sheet and excess cash,” which allows it to pursue strategic financial initiatives, including diversifying treasury holdings with Bitcoin while maintaining its focus on advancing clinical trials and shareholder returns.
“With Bitcoin’s growing recognition as a mainstream asset class, we believe it represents a valuable addition to our treasury reserve strategy. The approval of Bitcoin ETFs and increasing participation from institutional investors highlight its rising importance in global markets.”
Mike Catelani, president and CFO of Anixa
Anixa’s chief executive Amit Kumar highlighted the firm’s disciplined approach to financial management, stating that the Bitcoin allocation is an “additional approach to prudent financial management, enabling greater shareholder value.” Following the announcement, Anixa shares soared 7.84% in pre-market trading.
Public companies rush to embrace Bitcoin as treasury asset
The move aligns with a growing trend among public companies incorporating Bitcoin into their financial strategies. Artificial intelligence firm Genius Group recently also announced $4 million in BTC purchases, raising its holdings to 153 BTC as part of its “Bitcoin-first” strategy to allocate 90% or more of its reserves to the cryptocurrency.
Other companies, including MicroStrategy and Nasdaq-listed Acurx, have also expanded their Bitcoin holdings to capitalize on its role as a hedge against inflation and a store of value supporting technological innovation.
